Clinical Trials Browser

Phase 2 × ibrutinib × Dermatologic × Clear all

NCT02581930 2025-09-08

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Phase 2 Active not recruiting

18 enrolled 10 charts

Melanoma